BRAF mutations were addressed in depth this year, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.
BRAF mutations were addressed in depth this year on AJMC.com’s skin cancer page, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.
Here are the top 5 most-read skin cancer articles of 2022.
5. Dr Sigrun Hallmeyer Highlights Clinical Achievements and Barriers in Melanoma
In this interview with Sigrun Hallmeyer, MD, medical director of Advocate Lutheran General Hospital’s Cancer Service Line and codirector of medical research at Advocate Aurora Health, in Illinois, she addresses several important topics regarding melanoma. Chief among them are top goals for treating patients with advanced disease, the impact of social determinants of health on patient outcomes, and the effects of payer decisions regarding coverage, diagnosis, and treatment. Treatment resistance and cancer survivorship are also discussed.
4. Dabrafenib Plus Trametinib Approved as First Tumor-Agnostic Therapy for BRAF V600E–Mutated Solid Tumors
Adult and pediatric patients who have solid tumors with a BRAF V600E mutation received good news in June with the FDA’s approval of the combination treatment, the first therapy to be approved by the agency for a tumor-agnostic indication in these patient populations. Accounting for up to 90% of BRAF-mutant cancers, the indication for BRAF V600E came after dabrafenib plus trametinib demonstrated safety and efficacy in 3 clinical trials: for adults, the phase 2 Rare Oncology Agnostic Research and the NCI-MATCH Subprotocol H studies, and for children, Study X2101.
3. Neurofibromatosis Type 1 Linked to Greater Skin Cancer Risk
Risks for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), keratinocyte carcinoma (KC), and melanoma were higher among a cohort of patients who lacked neurofibromin, a tumor suppressor gene. Not having this gene can lead to the development of benign skin, eye, and nervous system tumors and a potentially higher risk of nervous system or other solid organ cancers. The risk for BCC was 30% higher; SCC, 32%; KC, 31%; and melanoma, 127%. A subanalysis of outcomes among patients of various ethnicities found that Hispanic patients and Black patients had the highest risks of KC vs comparable risk among White patients and Asian patients.
2. Dr Martin Dietrich Describes Need to Move Quickly With “Aggressive, Unpredictable” Melanoma
In this interview, Martin Dietrich, MD, PhD, of Florida Cancer Specialists, discusses melanoma risk factors, genomic testing, and the importance of prompt action—because melanoma is known for rapidly advancing. Dietrich also addresses the impact that the BRAF V600E mutation can have in the space, as well as non-V600 mutations, and goes into detail about potential longer-term benefits from sequencing targeted therapy then immunotherapy instead of immunotherapy and then targeted treatment. He closes with an in-depth discussion on melanoma disease management considerations, noting that immunotherapy comes with certain long-term consequences but is often the default treatment because “of the simplicity” and more discussions need to be held around how to manage patients with locally advanced metastatic melanoma.
1. ctDNA Accurately Detects BRAF Mutations in Advanced Melanoma, Study Finds
With advantages that include minimal invasiveness, low cost, reproducibility, and shortened wait times for results, liquid biopsy via analysis of circulating tumor DNA (ctDNA) was shown in this March piece to “be a viable option for determining the presence of BRAF mutations in patients with advanced melanoma.” With tissue samples often difficult to obtain when wanting to assess BRAF mutation status, the study authors highlighted that liquid biopsy is considered a simpler option, even though a majority of its use takes place in clinical trials and research settings—so that wider use remains very limited.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More